UNSPSC 51294301: Quisultazine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C21H25N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 60J29WG4Q6 chemically known as 10h-phenothiazine-2-sulfonamide, 10-(1-azabicyclo(2.2.2)oct-3-yl)-n,n-dimethyl- but generally known as quisultazine, which bears US NIH Compound Identifier 68833. European Medicines Agency schedules Quisultazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10228MIG.

UNSPSC 51294301 Quisultazine, a Commodity code, shows minimal alignment between the nominal taxonomy name and recent state and local procurement activity. The code appears in three recent solicitations, but only one—Seminole County, Florida's purchase of naloxone and drug deactivation systems—involves a pharmaceutical product with any plausible connection to the quisultazine drug class. The other two opportunities (Texas HHS's RFI on direct-to-manufacturer prescription programs and Minnesota MMCAP's generic multi-source pharmaceutical and OTC products RFP) concern pharmacy benefit administration, contracting frameworks, and general pharmaceutical supply rather than a specific active pharmaceutical ingredient. The Seminole County IFB reflects concrete procurement of naloxone as a community health initiative product with defined unit volumes (1,900 units annually) and quarterly delivery schedules, but this is a harm-reduction pharmaceutical, not quisultazine. The code does not show robust recent activity tied to quisultazine specifically.

Recent opportunities span Florida, Texas, and Minnesota, with the Seminole County IFB (posted June 30, 2026, due July 26, 2023—a date inconsistency in the source) representing the most concrete pharmaceutical-product purchase. The Texas HHS RFI (posted April 3, 2026) and Minnesota MMCAP RFP (posted January 20, 2026, due March 26, 2026) both involve broader pharmaceutical supply and contracting strategy rather than procurement of quisultazine as a line item. Issuing bodies include a county health system, a state health and human services commission, and a multistate cooperative purchasing alliance. Given the sparse and misdirected tagging of opportunities under this code, state and local buyers do not appear to be actively procuring quisultazine in identifiable volumes or through dedicated solicitations at this time.